Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IICompletedNov 2, 2022Quinapril and Hydrochlorothiazide TabletsCGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.Aurobindo Pharma USA Inc. · D-0021-2023Class IITerminatedNov 2, 2022Fondaparinux Sodium InjectionSubpotent Drug: Out of specification for assayAuroMedics Pharma LLC · D-0020-2023Class ITerminatedNov 2, 2022Atenolol TabletsLabel Mix - up; a bottle labeled as Atenolol 25mg Tablets contained Clopidogrel 75mg TabletsGolden State Medical Supply Inc. · D-0019-2023Class IITerminatedNov 2, 2022Pyridostigmine Bromide Oral SolutioncGMP Deviations: Out of specification for assay of one of the preservative ingredients.VistaPharm, Inc. · D-0018-2023Class IITerminatedNov 2, 2022Proton ArmorChemical Contamination and CGMP Deviations: trace amounts of methanol found in one of the components during the manufacturing process.Ultra Chem Labs Corp · D-0017-2023Class IITerminatedNov 2, 2022Proton ArmorChemical Contamination and CGMP Deviations: trace amounts of methanol found in one of the components during the manufacturing process.Ultra Chem Labs Corp · D-0016-2023Class IIOngoingOct 26, 20220.9% Sodium Chloride InjectionLack of Assurance of Sterility: Leakage of 0.9% Sodium Chloride for Injection, 1L, 12pk Saline Solution.Fresenius Medical Care Holdings, Inc. · D-0015-2023Class IIITerminatedOct 26, 2022NDC 0363-6171-09 Walgreens Sinus PressureBoxes mislabeled to read "Decongestant Free", but the product contains Phenylephrine HCI 5mgLNK International, Inc. · D-0014-2023Class IICompletedOct 26, 2022Acyclovir Sodium InjectionPresence of Particulate Matter: Customer complaint for a dark red, brown and black particulate floating inside vial.AuroMedics Pharma LLC · D-0013-2023Class IITerminatedOct 26, 2022Rifampin CapsulesFailed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).Golden State Medical Supply Inc. · D-0012-2023Class IITerminatedOct 26, 2022Rifampin CapsulesFailed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).Golden State Medical Supply Inc. · D-0011-2023Class IICompletedOct 26, 2022Flunisolide Nasal SolutionOut of specification for related substances (impurities).Ingenus Pharmaceuticals Llc · D-0010-2023Class IITerminatedOct 19, 2022Skincell Mole & Skin Corrector SerumMarketed Without An Approved NDA/ANDA; Unapproved new drugJustified Laboratories · D-0009-2023Class IITerminatedOct 19, 2022Skincell Mole & Skin Corrector SerumMarketed Without An Approved NDA/ANDA; Unapproved new drugJustified Laboratories · D-0008-2023Class IIIOngoingOct 12, 2022Tranexamic Acid InjectionPresence of Particulate Matter: Piece of metal found in a vialAuroMedics Pharma LLC · D-1551-2022Class IITerminatedOct 12, 2022Arformoterol Tartrate Inhalation SolutionLack of Assurance of Sterility: environmental monitoring failure.Cipla · D-1550-2022Class IIICompletedOct 12, 2022Phytonadione Injectable Emulsion USPFailed Stability Specifications: Out of specification results reported at 12-month stability testing for aluminum content.Dr. Reddy's Laboratories, Inc. · D-0007-2023Class IIITerminatedOct 12, 2022Antibacterial Foaming Wash with Hydria Moisturizing FormulaLabeling: Not Elsewhere Classified - Incorrect label-incorrect scent listed on label.Woodbine Products Co Inc · D-0006-2023Class IITerminatedOct 12, 2022Aminophylline InjectionPresence of Particulate Matter: A complaint was received for the presence of a hair in one vial.Pfizer Inc. · D-0003-2023Class ITerminatedOct 12, 2022Antica Farmacista Hand Sanitizer Ocean CitronChemical Contamination: product found to contain benzeneSalon Technologies International Inc · D-0002-2023Class IITerminatedOct 12, 2022Sanitizing Hand Spray 80%GMP Deviations: FDA analysis found product to contain acetaldehyde and acetal above specification limits.Salon Technologies International Inc · D-0001-2023Class IIITerminatedOct 5, 2022XolegelFailed Viscosity specification: Slightly higher OOS results obtained for viscosityAlmirall, LLC · D-1549-2022Class IIOngoingOct 5, 2022Rifampin CapsulesFailed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).Akorn, Inc. · D-1548-2022Class IIOngoingOct 5, 2022Rifampin CapsulesFailed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).Akorn, Inc. · D-1547-2022Class IIITerminatedOct 5, 2022ClomiPRAMINE Hydrochloride CapsulesSuperpotent Drug: Assay value found to be 110.6% in Chlomipramine Hydrocholoride capsulesLeading Pharma, LLC · D-1546-2022Class IITerminatedOct 5, 2022Budesonide Inhalation Suspension 0.25mg/2mLLack of Assurance of SterilityCipla · D-1545-2022Class IIITerminatedOct 5, 2022oxyTOCIN 30 Units/500 mLIncorrect Product Formulation: Oxytocin 30 units was added to an IV bag of 0.45% Sodium Chloride (500mL) instead of 0.9% Sodium Chloride (500mL).QuVa Pharma, Inc. · D-1544-2022Class IITerminatedOct 5, 2022Neoral soft gelatin capsulesCGMP deviations: Out of specification results obtained during routine stability testing for ethanol content.Novartis Pharmaceuticals Corporation · D-1543-2022Class IITerminatedOct 5, 2022Ampicillin for InjectionPresence of Particulate Matter: A complaint was received for the presence of a single strand of hair in one vial.Viatris Inc · D-1542-2022Class IIITerminatedOct 5, 2022Esomeprazole Magnesium Delayed-Release CapsulesSuperpotent Drug: Out of specification for assay at the 12-month timepoint.Sun Pharmaceutical Industries Inc · D-0005-2023Class IIITerminatedOct 5, 2022Esomeprazole Magnesium Delayed-Release CapsulesSuperpotent Drug: Out of specification for assay at the 12-month timepoint.Sun Pharmaceutical Industries Inc · D-0004-2023Class IIITerminatedSep 28, 2022Clonidine Hydrochloride TabletsProduct mix-up:0.2 mg strength Clonidine Hydrochloride Tablets, USP in a 100-count bottle of 0.3 mg strength Clonidine Hydrochloride Tablets,Unichem Pharmaceuticals USA Inc · D-1541-2022Class ITerminatedSep 21, 2022PROPOFOL Injectable EmulsionPresence of particulate matterPfizer Inc. · D-1540-2022Class IITerminatedSep 21, 2022Dextroamphetamine SaccharateLabeling: Label Error on Declared Strength; A sealed 100-count bottle labeled with 15 mg actually contained 100 tablets of 20 mg strength of the drug product.Teva Pharmaceuticals USA Inc · D-1539-2022Class IITerminatedSep 21, 2022Lisinopril 10 mg tabletsPresence of Foreign Substance: Foreign material (metal piece) embedded in one tablet.RemedyRepack Inc. · D-1538-2022Class IITerminatedSep 21, 2022Synergy Hand SanitizerCGMP Deviations: FDA analysis found product to contain acetaldehyde impurity and the Sum of All Impurities, above specification limits.Superior Glove Works, Ltd. · D-1537-2022Class IITerminatedSep 21, 2022Lisinopril Tablets USPPresence of Foreign Substance: Foreign material (metal piece) embedded in one tablet.Lupin Pharmaceuticals Inc. · D-1536-2022Class IICompletedSep 21, 2022Triamcinolone Acetonide creamCGMP Deviations: Product complaints reporting the product to have a gritty texture and lack of effectiveness.Direct Rx · D-1535-2022Class IICompletedSep 21, 2022QUAD-MIX 30MG/3MG/60MCG/0.2 InjectableLack of Assurance of SterilityCarolina Infusion · D-1534-2022Class IICompletedSep 21, 2022QUAD-MIX 30/2/60/0.15 InjectableLack of Assurance of SterilityCarolina Infusion · D-1533-2022